Heroin Overdose Reversal Drug Recalled

Comments (0)

A voluntary recall has been issued by the drug manufacturer Teleflex for its heroin and opioid overdose antidote. The drug is administered with a syringe-like device, which sprays the drug into the nose. The manufacturer issued a letter last week to distributors announcing the devices were being recalled because they may not deliver a “fully atomized plume” of medication. The company received complaints that the device was producing a straight stream instead of an atomized spray.

Because of the stream instead of the mist, the drug isn’t as effective. It does not cover as much surface area, and therefore there is less absorption. The company received six complaints, but not reports of serious injury or death. Teleflex has notified the Food and Drug Administration of the recall, although it was not legally required to do so.

According to the Centers for Disease Control, there has been a 200 percent increase in the rate of opioid overdose deaths, which includes heroin and prescription narcotics. Drug overdoses are the leading cause of accidental death in the U.S. Between 1996 and 2014, over 150,000 naloxone kits have been distributed to non-medical and non-first responder individuals. There have been at least 26,000 overdoses reversed with those kits.

Patients rely on drugs being delivered as promised, with the desired results. In some cases, a patient does not react well to prescription drugs through no fault of the drug manufacturer. However, in other cases the drug company failed to properly test or manufacture the drug, or to warn of side effects.

If you have been harmed by a prescription drug in Houston, call the Houston prescription drug defect attorneys at Kennedy Hodges at 855-947-0707. We can help. Call today for a free consultation or visit us on Google Plus.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."

Name:*

Email:* (will not be published)

Message:*

Notify me of follow-up comments via email.